Clinical Research
News & Careers
Search the Site
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login           Employers:  Register | Login   

By Industry | By Industry Segment | By Services and Suppliers | By Location | Profile Search
 Company Profile


Bristol-Myers Squibb Company 

345 Park Avenue

New York  New York  10154  U.S.A.
Phone: 212-546-4000 Fax: 212-546-4020


 Key Statistics

Ownership: Public

Web Site: Bristol-Myers Squibb Company
Symbol: BMY


Gilead Sciences, Inc. 

PanVera LLC 

Pharmagene Laboratories Limited 

Johnson & Johnson 

Amersham Biosciences 

Lexicon Genetics Incorporated 

Athersys, Inc.  Athersys will provide Bristol-Myers Squibb with cell lines expressing validated drug targets produced using the RAGE-Validated Target technology. BMS plans to use its combinatorial chemistry capabilities to develop small molecule drug candidates against the validated targets.

Merck & Co., Inc.  Diabetes

Affinimark Technologies Inc. 

GlaxoSmithKline (North Carolina) 

Medarex, Inc. 

Gilead Sciences, Inc. (Durham, NC) 

Phyton Biotech, Inc.  - Cancer

Gilead Sciences, Inc. (Seattle, WA) 

 Company News
Bristol-Myers Squibb Company (BMY) Taps Bay Area's Redwood City For Expansion, Pharma Giant To Increase Workforce 7/25/2014 8:42:00 AM
Bristol-Myers Squibb Company (BMY) And Ono Pharmaceutical Company, Ltd. Announce Strategic Immuno-Oncology Collaboration In Japan, South Korea And Taiwan 7/24/2014 11:34:28 AM
Bristol-Myers Squibb Company (BMY) And Pfizer Inc. (PFE) Announce Enrollment Of First Patient In Phase IV EMANATE Trial To Assess Effectiveness And Safety Of Eliquis® (Apixaban) In Patients With NVAF Undergoing Cardioversion 7/17/2014 9:42:56 AM
Bristol-Myers Squibb Company (BMY) Announces Plans For Third Quarter Submission Of A Biologics License Application For Opdivo® (Nivolumab), An Investigational PD-1 Immune Checkpoint Inhibitor, For Previously Treated Advanced Melanoma 7/10/2014 10:03:51 AM
Bristol-Myers Squibb Company (BMY) Release: Japan Approves First All-Oral, Interferon- And Ribavirin-Free Hepatitis C Treatment, Daklinza® (Daclatasvir) And Sunvepra®(Asunaprevir) Dual Regimen 7/7/2014 11:27:00 AM
Bristol-Myers Squibb Company (BMY), Pfizer Inc. (PFE)'s Clot Drug Eliquis® Gets EU Green Light For Wider Use 6/27/2014 6:41:01 AM
Bristol-Myers Squibb Company (BMY)'s Hepatitis C Drug Daklinza Receives Positive CHMP Opinion 6/27/2014 6:36:30 AM
Bristol-Myers Squibb Company (BMY) Stops Skin Study On Positive Phase 3 Data 6/24/2014 4:54:43 PM
Bristol-Myers Squibb Company (BMY) Ties It Up With Duke University In Bid To Focus On Clinical Trial Transparency 6/24/2014 6:08:35 AM
Bristol-Myers Squibb Company (BMY) Announces Dividend 6/18/2014 11:19:12 AM